口服司美格鲁肽对比西格列汀在以中国人群为主的二甲双胍控制不佳的2型糖尿病患者中的疗效与安全性:PIONEER 12,一项双盲、IIIa期、随机试验
PIONEER 12是一项为期26周的双盲IIIa期随机试验,纳入1441例以中国人群为主、二甲双胍控制不佳的2型糖尿病患者,比较口服司美格鲁肽3/7/14 mg与西格列汀100 mg。各剂量司美格鲁肽较西格列汀显著降低HbA1c和体重,胃肠道不良事件最常见但多为短暂轻中度。
要点
- 口服司美格鲁肽3/7/14 mg较西格列汀100 mg显著降低26周HbA1c。
- 口服司美格鲁肽各剂量较西格列汀100 mg显著降低26周体重。
- 最常见不良事件为胃肠道反应,多为短暂轻中度。
核心结论
- 在以中国人群为主、二甲双胍控制不佳的2型糖尿病患者中,口服司美格鲁肽3 mg、7 mg和14 mg较西格列汀100 mg在26周时显著降低HbA1c和体重。
- 口服司美格鲁肽总体耐受性良好,安全性特征与全球PIONEER试验一致。
研究设计与样本
- PIONEER 12为随机、双模拟、活性对照、平行组IIIa期试验,为期26周,在中国地区(包括中国大陆、台湾和香港)及其他五个国家的90个中心开展。
- 纳入年龄≥18岁(台湾≥20岁)、诊断为2型糖尿病、HbA1c在53至91 mmol/mol(含)之间且接受稳定日剂量二甲双胍治疗的成人。
- 参与者按1:1:1:1随机分配至每日一次口服司美格鲁肽3 mg、7 mg、14 mg或每日一次口服西格列汀100 mg,参与者和研究者均设盲。
- 随机化按是否来自中国地区分层;筛查1839例,随机分配1441例纳入全分析集(FAS),1438例纳入安全性分析集(SAS)。
主要发现
- 从基线至第26周HbA1c降幅:口服司美格鲁肽3 mg、7 mg、14 mg对比西格列汀100 mg的估计治疗差异(ETD[95%CI])分别为-2(-4,-1)mmol/mol、-8(-9,-6)mmol/mol和-11(-12,-9)mmol/mol。
- 对应的百分数ETD(95%CI)对比西格列汀100 mg分别为-0.2(-0.3,-0.1)、-0.7(-0.8,-0.6)和-1.0(-1.1,-0.8)。
- 体重降幅:口服司美格鲁肽3 mg、7 mg、14 mg对比西格列汀100 mg的ETD(95%CI)分别为-0.9(-1.4,-0.4)kg、-2.3(-2.8,-1.8)kg和-3.3(-3.8,-2.8)kg。
- 来自中国地区的参与者亚组(占75.2%)从基线至第26周HbA1c和体重降幅与总体人群相似。
- 司美格鲁肽治疗组最常见不良事件为胃肠道事件,但多为短暂且轻/中度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to assess the efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes inadequately controlled with metformin treatment. METHODS: The Peptide Innovation for Early Diabetes Treatment (PIONEER) 12 trial was a randomised, double-dummy, active-controlled, parallel-group, Phase IIIa trial conducted over 26 weeks at 90 sites across the China region (including mainland China, Taiwan and Hong Kong) and five other countries. Adults aged ≥18 years (≥20 years in Taiwan) with a diagnosis of type 2 diabetes, HbA1c between 53 and 91 mmol/mol (inclusive) and treated with a stable daily dose of metformin were eligible for inclusion. Participants were randomised (1:1:1:1) using a web-based randomisation system to either once-daily oral semaglutide (3 mg, 7 mg or 14 mg) or once-daily oral sitagliptin 100 mg. Treatment allocation was masked to both participants and investigators. Randomisation was stratified according to whether participants were from the China region or elsewhere. The primary endpoint was change in HbA1c from baseline to week 26. The confirmatory secondary endpoint was change in body weight (kg) from baseline to week 26. All randomised participants were included in the full analysis set (FAS). All participants exposed to at least one dose of trial product were included in the safety analysis (SAS). RESULTS: Of 1839 participants screened, 1441 were randomly assigned to oral semaglutide 3 mg (n=361), 7 mg (n=360), 14 mg (n=361) or sitagliptin 100 mg (n=359) and included in the FAS. A total of 1438 participants were included in the SAS. In total, 75.2% of participants were from the China region. A total of 1372 (95.2%) participants completed the trial and 130 participants prematurely discontinued treatment (8.3%, 8.6% and 15.0% for oral semaglutide 3 mg, 7 mg and 14 mg, respectively; 4.2% for sitagliptin 100 mg). Significantly greater reductions in HbA1c from baseline to week 26 were reported for all doses of oral semaglutide vs sitagliptin 100 mg. For oral semaglutide 3 mg, 7 mg and 14 mg vs sitagliptin 100 mg, the estimated treatment differences (ETDs [95% CI]) were -2 (-4, -1) mmol/mol, -8 (-9, -6) mmol/mol and -11 (-12, -9) mmol/mol, respectively. The corresponding ETDs (95% CI) in percentage points vs sitagliptin 100 mg were -0.2 (-0.3, -0.1), -0.7 (-0.8, -0.6) and -1.0 (-1.1, -0.8), respectively. Reductions in body weight were significantly greater for all doses of oral semaglutide vs sitagliptin 100 mg (ETD [95% CI] -0.9 [-1.4, -0.4] kg, -2.3 [-2.8, -1.8] kg and -3.3 [-3.8, -2.8] kg for 3 mg, 7 mg and 14 mg, respectively). In the subpopulation of participants from the China region (75.2% of trial participants), reductions in HbA1c and body weight from baseline to week 26 were similar to those seen in the overall population. The most frequent adverse events in the semaglutide treatment arms were gastrointestinal, although these were mostly transient and mild/moderate in severity. CONCLUSIONS/INTERPRETATION: Significantly greater reductions in both HbA1c and body weight over 26 weeks were seen with oral semaglutide 3 mg, 7 mg and 14 mg than with sitagliptin 100 mg in a predominantly Chinese population with type 2 diabetes inadequately controlled with metformin treatment. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT04017832. FUNDING: This trial was funded by Novo Nordisk A/S, Søborg, Denmark.
引用
- Ji L, Agesen RM, Bain SC, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024. PMID: 38985161. doi:10.1007/s00125-024-06133-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。